drugset
drugset / Trial / NCT04194242

The Tolerability , Pharmacokinetics and Pharmacodynamics Study of HEC96719 Tablets in Healthy Adult Subjects

NCT04194242 ↗

Phase 1 Completed 64 enrolled Sunshine Lake Pharma Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a safety, tolerability, and pharmacokinetics phase Ⅰstudy of HEC96719, in healthy subjects.This study is the healthy adult subjects single ascending-dose research

Timeline

Start
2020-01-03
Primary completion
2020-07-17
Completion
2020-07-17

Drugs

EvaluationDrugModalityDoseRoute
Subject HEC96719 Unknown 0.1 mg Oral
Subject HEC96719 Unknown 0.2 mg Oral
Subject HEC96719 Unknown 0.5 mg Oral
Subject HEC96719 Unknown 1 mg Oral
Subject HEC96719 Unknown 2 mg Oral
Subject HEC96719 Unknown 3 mg Oral
Subject HEC96719 Unknown 4 mg Oral

Indications

metabolic dysfunction-associated steatohepatitis